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tonin-norepinephrine retake inhibitors (SNRIs) and Tricyclic Antidepressants (TCAs) 
are used for the short-term treatment of neuropathic pain. The cost-effectiveness of 
these three medications in Canada was examined. METHODS: A decision-tree ana-
lytic model compared the three drugs, over 18 weeks. Response rates were determined 
from two meta-analyses, “From-Placebo” and “Through-Placebo”. Outcomes of 
interest were rates of achieving 50% reduction in baseline pain (full-response) or 30% 
reduction (partial-response). A secondary outcome was the number of pain-controlled 
days (PCDs) applying full-response. The Ministry of Health (MOH) perspective
applied direct medical costs: medications, physician visits, diagnostic tests, and hos-
pitalizations; societal perspective (SOC) also applied indirect costs (productivity loss);
all in CN$2007. RESULTS: The “From-Placebo” approach yielded MOH (SOC) costs
of $380 ($1808); $448 ($2030); and $560 ($2063) for TCAs, SNRIs and ACs, respec-
tively, while primary outcomes were 79.3%; 76.4%; and 77.8%, and secondary
effective outcomes were 48 PCDs, 43 PCDs; and 46 PCDs for the same sequence. The
“Through-Placebo” approach yielded MOH (SOC) costs of $331 ($1513); $459
($1868); and $519 ($2125) for TCAs, SNRIs, and ACs, respectively, with primary 
(secondary) effectiveness outcomes of 88.0% (60 PCDs), 80.6% (41 PCDs); and 
84.3% (54 PCDs), for the same sequence. CONCLUSIONS: For both approaches,
TCAs provided the least costly alternative, and better outcomes, for both for primary 
and secondary effectiveness measures, effectively dominating SNRIs and ACs.
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OBJECTIVES: Development of a cost effectiveness analysis to evaluate treatment 
options for haemophilia patients with inhibitors in Germany. METHODS: Costs and 
outcomes of four different treatment regimens were compared by using an Excel-based
Markov model with a three month cycle length. Comparators are low- and high dose
protocols vs. strict on-demand treatment and to a mixture of both protocols after 
conducting a risk assessment. Time horizon: 18 years. Success rates of the different 
ITI-protocols, rates of anamnestic response, bleeding event rates and success rates for 
the treatment of bleeds were obtained from the literature. Costs included the costs for 
factor concentrates and hospitalization. Costs for one average patient were reported 
from a third party payers’ perspective. Annually discounting rates were 3% for costs
and 5% for beneﬁ ts. RESULTS: One average patient treated on-demand costs
€1,558,962.54 and has 181.92 minor and 2.43 severe bleeds. The cost for the same 
patient treated with the high dose ITI-protocol is approximately double (€3,340,976.81), 
but the patient has 2/3 fewer bleeds. The incremental cost per additional avoided 
minor bleed compared to on-demand treatment is €14,816.77 for the high dose pro-
tocol, €9,716.50 for ITI after risk assessment and €8,938.84 for the low dose protocol. 
The incremental costs per avoided bleed is €12,810.19 more for ITI after risk assess-
ment than for the low dose ITI protocol. When comparing the high dose ITI protocol
vs. ITI after risk assessment, each avoided bleed costs an extra €313,417.11. CON-
CLUSIONS: The results of the model suggest that use of risk assessment is the most 
cost effective approach to ITI. Although data on rare diseases are scarce and hard to
compare, decision-analytic modelling is a valuable tool to weight the costs and con-
sequences of different treatment regimens for patients with severe haemophilia com-
plicated by inhibitors.
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OBJECTIVES: To determine whether a Behavioral Internet Treatment (BIT) program 
for weight management is a viable cost-effective option, compared to the usual
care in a diverse sample of overweight (average BMI  29 kg/m2) healthy adults (mean
age 34) of the United States Air Force (USAF). METHODS: A 2-group parallel-
randomized controlled trial (N  442) outcomes were considered for this economic 
evaluation. Participants were randomly assigned into two groups 1) Usual Care (UC,
N  215) and 2) Usual Care plus Behavioral Internet Therapy (BIT, N  227). Individu-
als were evaluated twice, at baseline and at 6 months. Only statistically signiﬁ cant
primary outcome measures (changes in body weight, percent body weight changes and 
waist circumferences) and a secondary outcome measure (Weight Efﬁ cacy Life Style 
Questionnaire/WEL) were included in incremental cost effectiveness analysis (ICEA)
model. Costs of the intervention were computed by using the perspective of an agency 
wanting to replicate the intervention. Intervention costs consisted of: recruiting and 
training of telephone counselors, orientation, baseline and follow up appointments, 
paperwork and measurement costs. One-way sensitivity analyses were performed to
measure the robustness of this ICEA model. RESULTS: The intervention produced a
total direct cost of $7,993.32 for BIT intervention with a cost of $35.21/BIT partici-
pants. Total staff time costs were $64.58/BIT participants. The overall cost for the 
entire BIT intervention was $22,653.92 or $99.80/BIT participants. Intervention cost 
was $52.52 for each additional kg of weight loss. Additionally, intervention costs were
$58.70 for each cm waist circumference loss. On the WEL subscales costs were $76.77 
for each additional point gained on the social pressure subscale; where increasing 
scores indicate increased conﬁ dence in managing social pressures to eat. CONCLU-
SIONS: Although different forms of weight management program exist, the Behavioral 
Internet Therapy program is found to be a cost-effective choice for weight manage-
ment. Internet Therapy program is costly initially, but may provide a cost-saving 
long-term impact.
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OBJECTIVES: A variety of anti-TNF agents have been approved for the treatment of 
multiple autoimmune disorders. The objective of the current study is to compare the 
cost-effectiveness of these biologics across each drug’s approved therapeutic indica-
tions. METHODS: A systematic literature review was conducted of journal articles 
published during the period of 1998 to 2008 to identify all relevant cost-effectiveness 
analyses investigating the following three multiple indication drugs: adalimumab, 
etanercept, and inﬂ iximab. Speciﬁ cally, for adalimumab cost-effectiveness results were
analyzed for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis (PsO), 
and Crohn’s disease (CD); for etanercept cost-effectiveness results were analyzed for
RA, AS, and PsO; and for inﬂ iximab cost-effectiveness results were analyzed for RA,
AS, PsO, psoriatic arthritis (PsA), CD, and ulcerative colitis (UC). For each of the 
three therapies, the incremental cost-effectiveness ratios (ICERs) among their various
indications were compared. All costs were converted to 2007 USD using the Consumer 
Price Index (CPI) and Purchasing Power Parities (PPP) for comparison. RESULTS: A 
total of 25 cost-effective evaluations were included for comparative analysis. While 
all studies found adalimumab, etanercept and inﬂ iximab to be cost-effective for at 
least one indication (using a threshold of $50,000 – $100,000/QALY gained), ICER
values across approved indications varied greatly; for example, for inﬂ iximab, ICER
values as high as $290,000 were reported the treatment of RA, $75,000 for the treat-
ment of AS, $46,000 for the treatment of PsA, and $60,000 for the treatment of CD.
Reported ICER values for each indication also varied among studies as a result of 
differences between comparators, analytic timeframes, and study perspectives. CON-
CLUSIONS: Based on published ICER values, the cost-effectiveness of multiple indica-
tion drugs varies across approved indications. From an economic standpoint, although 
various biologic agents have approval for several indications, these drugs do not neces-
sarily offer a cost-effective solution across all approved indications.
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OBJECTIVES: The aim of this study was to assess the incremental cost-effectiveness
of on-demand versus prophylactic haemophilia therapy in Iran from the third-party
payers’ perspective. METHODS: A retrospective chart review of 25 types A haemo-
philiacs that treated in 3 hemophilia treatment center was conducted for patients aged
0–9 years receiving one of two treatments: 1) prophylaxis with concentrate at clinic;
2) concentrate at clinic as on-demand. Fourteen boys receiving on-demand infusions
for bleeding events and 11 boys receiving infusions prophylaxis. Data were collected
from documents obtained from the hemophilia treatment centers during a period of 
approximately 6 months. RESULTS: The patients receiving prophylactic treatment 
had fewer bleeding events each month (mean, 0.26 vs. 2.74) but used more concentrate
(225.31 vs. 87.20 units / kg per month). Average cost per patient each month at pro-
phylaxis group was about 1.9 times higher than on-demand group. Compared with 
on-demand infusion, prophylaxis costs 3201656 Rials (US $ 356) per bleeding event 
prevented. CONCLUSIONS: Prophylactic care markedly reduces the number of bleed-
ing episodes, but at considerable cost.
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OBJECTIVES: Patients with ﬁ bromyalgia (FM), a major cause of morbidity, use health 
services extensively and have an estimated prevalence of 3.4% for women and 0.5%
for men. The aim of this study was to assess the cost-effectiveness of pregabalin in 
the treatment of FM from the health care payer’s perspective. METHODS: We devel-
oped a three-state Markov model to simulate health and economic outcomes during
a time horizon of one-year (12-week cycles). The model includes several stages related 
to functional disability (mild-pain, moderate-pain and severe-pain). Effectiveness was 
assumed as the percentage of patients with no or mild pain (pain score 4) at the end 
of the follow-up period using a Visual Analogue Scale(VAS). Transition probabilities 
were obtained from a systematic review involving national and international published 
trials. Comparators used in the assessment were amitriptyline (25–50 mg/day); prega-
balin (150–450 mg/day); ﬂ uoxetine (20–80 mg/day); duloxetine (60–120 mg/day); 
gabapentin(300–1200 mg/day); tramadol(150–1300 mg/day)  acetaminophen(325–
2600 mg/day) and ﬂ uoxetine(20–80 mg/day)  amitriptyline(10–50 mg/day). Resource 
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use and costs were obtained from 5000 randomized hospital records from the Social 
Security Mexican Institute(IMSS) and ofﬁ cial institutional databases. Costs include 
outpatient and inpatient services, drug, procedures, etc. The model was validated 
according to international guidelines. Probabilistic sensitivity analyses were performed 
employing bootstrapping techniques and acceptability curves were constructed. 
RESULTS: The highest percentage of patients with no or mild pain during the follow-
up period was obtained by pregabalin(44.8%; CI95% 42.8%–48.0%); followed 
by gabapentin(38.1%; CI95% 33.2%–43.5%); duloxetine(34.2%; CI95% 27.8%–
40.6%) and amitriptyline(22.2%; CI95% 21.0%–24.0%).The annual expected
mean costs per patient were US$1503.2(US$1472.2–US$1534.09); US$1,742.7
(US$1,715.1–US$1,770.2); US$2,046.6(US$2018.6–US$2074.7) and US$643.6(US$615.2–
US$673.5), respectively. The ICER of pregabalin vs. amitriptyline(basecase) was
US$3798.9(US$3336.1–US$4,325.9). Other treatments were dominated by pregaba-
lin. Second-order Monte Carlo sensitivity analyses indicated that pregabalin would be 
a cost-saving strategy in a range of 60%–70% within accepted thresholds(p  0.05). 
CONCLUSIONS: In Mexico, pregabalin showed to be a cost-effective and cost-saving 
therapy when compared with amitriptyline and other usual treatments in the manage-
ment of FM.
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OBJECTIVES: Haemophilia A is a hereditary genetic disorder with a relatively high 
burden of disease from the perspective of both society and the individual patient. 
Kogenate FS is a second-generation full-length recombinant factor VIII (FVIII), pro-
duced without the addition of human albumin during formulation. It shows lower
incidence of inhibitors compared with other recombinant factor VIII products, which 
has an impact on economic evaluation because the haemophilia patients with inhibi-
tors have to be treated with a signiﬁ cantly higher dosage or expensive bypassing
agents. The main objective of this study is to conduct economic evaluation of Kogenate
FS compared with Recombinate in haemophilia A patients in Korea. METHODS: A 
cost-minimization analysis was performed under the assumption that Kogenate FS and 
Recombinate were clinically equivalent for treating bleeding episodes. A decision-
analytic model was developed to estimate the lifetime costs by reﬂ ecting each different 
treatment strategies for haemophilia A patients with inhibitors or not. If patients had
inhibitors, it was ramiﬁ ed according to the inhibitor titres into one of three pathways: 
5BU, 5–10BU, and 10BU. The analysis was conducted based on the societal perspec-
tive, and costs were discounted at 5% annually. Sensitivity analyses were performed
on crucial parameters. RESULTS: Incidence of inhibitor for Kogenate FS and Recom-
binate were 8.113% and 16.9% respectively. Using the base case analysis, the expected 
cost for Kogenate FS was US$1,979,133 compared with $2,382,332 for Recombinate.
So, Kogenate FS is $403,199 lower than Recombinate during lifetime. The differences
were mainly due to the higher inhibitor treatment costs. One-way sensitivity analysis 
revealed stable across included parameters. CONCLUSIONS: This cost minimization
study identiﬁ ed that treatment of Kogenate FS appears to save costs compared with
treatment of Recombinate. By initiating and continuing Kogenate FS treatment, the 
economic burden associated with Haemophilia A can be reduced under Korean health 
care system.
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OBJECTIVES: To perform economical evaluation of darbepoetin alfa vs. epoetin
alfa in hemodialysis patients with anemia and chronic kidney disease. METHODS:
The modeled study was performed. Proportion of patients receiving alternative
eritropoesis-stimulating proteins (ESP) dosing regimen, efﬁ cacy and safety of drugs
were extracted from multicenter randomized study made by Nissenson et al (American 
Journal of Kidney Diseases 2002; 1:110–8). Cost of treatment with ESPs for 28 weeks
and cost-minimization ratio (CMR) were calculated from the Russian reimbursement 
system point of view. RESULTS: According to selected study, the efﬁ cacy and safety
proﬁ le of darbepoetin alfa was similar to that of epoetin alfa. Mean dose decrease 
from 63.18 Mg/wk to 54.18 Mg/wk was observed in darbepoetin alfa group, while mean 
dose increase from 12,706 to 13,639 was registered in epoetin alfa group during 28
weeks. The costs of used medications were the same for darbepoetin alfa and epoetin 
alfa (RUB230,148.1 vs. RUB 229,427.19 (USD7,292.4 vs. USD7,269.56). The cost 
of medical manipulations were less for darbepoetin alfa due to its reduced dosing fre-
quency (RUB2284.8 vs. RUB6854.8 (US$72.4 vs. USD217.2) accordingly). Cost-
minimization analysis showed that cost of treatment with darbepoetin alfa is less then
epoetin alfa (CER  RUB3384.7 (US$107.3)). Sensitivity analysis was made on the 
basis of model, constructed with data extracted from other study (Molina et al.,
Nephrologia 2004; 6). It conﬁ rmed the results of present work. CONCLUSIONS:
According to the model darbepoetin alfa seems to be as effective and safe as epoetin
alfa, but it takes fewer costs for treatment of anemia in hemodialysis patients with
chronic kidney disease due to low dosing frequency and dose saving effect.
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THE IMPACT OF OBESITY ON MEDICAL EXPENDITURE AND HEALTH
RELATED QUALITY OF LIFE
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OBJECTIVES: To quantify the effect of obesity on the total direct medical expenditure 
and health related quality of life in the population of the United States. METHODS:
Data from the MEPS’s Household Component (2006), a nationally representative 
survey of the U.S. civilian non-institutionalized population, was used. Analysis
accounted for the survey’s clusters, strata and sampling weights. Obesity was deﬁ ned
as body mass index q30. Direct medical expenditure attributable to obesity was esti-
mated under diverse econometric models to assess sensitivity to zero-mass, non-nega-
tive values and skewed distribution. Models compared were ordinary least-squares
(OLS) on raw and log-transformed expenditures (homoskedastic and heteroskedastic 
re-transformations), and generalized linear models (GLM) with log-link and Gamma/
Poisson families, including 2-part variants of these 5 models. Box-Cox test and Modi-
ﬁ ed Park’s test determined the link and family in the GLM models. LINK, RESET, 
Hosmer-Lemeshow and Pearson’s correlation test determined model ﬁ t, while Copas
test was employed for over-ﬁ tting and cross validation. Incremental expenditure from 
the method of recycled predictions summed over population with obesity gave the 
total expenditure. Impact of obesity on SF12 mental and physical health component 
was assessed by OLS. Covariates included age, gender, race, ethnicity, income, geo-
graphic-location, and comorbidity. RESULTS: The 2-part model of OLS on raw
expenditure was the only model to pass all the speciﬁ cation and cross-validation tests.
Based on this model, annual incremental expenditure of obesity was $1188.50 (95%
CI  $1183.70 to $1193.40). Total direct expenditure of obesity was $72 billion (95%
CI  $68.2 to $75.8 billion), nearly 3-fold increase compared to 1998 estimates. SF12
physical component score was lower by 3.7 (p  0.001) while the mental component
score was lower by 1.2 (p  0.001) for those with obesity. These decrements are similar
to those observed for diabetes or hypertension. CONCLUSIONS: Obesity exerts an 
enormous economic and humanistic burden on the U.S. civilian non-institutionalized
population.
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OBJECTIVES: To estimate the prevalence of asthma with obesity and the annual
medical costs attributable to obesity. METHODS: The cross-sectional analysis 
was conducted from adults aged 18–74 who participated in the 2003–2006 
Medical Expenditure Panel Survey. Total of 6670 asthma patients were identiﬁ ed
based on the self reported diagnosis or ICD-9-CM code of 493 after excluding 
patients with pregnancy, malignancy, kidney dialysis, immunodeﬁ ciency, or body-
mass-index(BMI) 18.5. These patients were classiﬁ ed as normal (BMI:18.5-25) or 
obese(BMI:q30). Total medical costs included ofﬁ ce based physician/outpatient visits, 
emergency room visit, or hospitalization except dental problems and injuries. Costs 
related to respiratory system diseases were costs associated with ICD-9-CM of 460–
516. The medical cost attributable to obesity was the difference between the observed 
cost and the predicted cost which was calculated using the parameters estimated from
obese patients. The parameters for obese patients were estimated using a generalized
linear model with a log link function and a gamma distribution after adjusting for
demographic, social-economic, and co-morbidity variables. All costs were converted 
to 2006 U.S. dollars using price indices. Data were analyzed using SAS/STATA. 
RESULTS: The age-adjusted prevalence of asthma in total population was 8.2% and 
that of asthma with obesity was 2.8% respectively. The average total medical treat-
ment costs in obese asthma patients were $5090 (95%CI:$4639–$5540), signiﬁ cantly 
higher than normal weight patients ($2,825;95%CI:$2291–$3359:p  0.001). After 
adjustments, the total medical costs attributable to obesity per patient were $3,960
(95%CI:$3,693–$4,228). Of that cost, $154 was attributable to respiratory system
diseases (95%CI:$48–$259) with the biggest increment in patients aged 65–74 old. 
CONCLUSIONS: Obesity is prevalent in general population as well as asthma
patients. The average medical cost attributable to obesity was signiﬁ cantly higher than 
normal weight asthma patients. Effective public programs aiming at educating the
importance of controlling weight are strongly recommended to diminish the economic
burden of obesity.
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OBJECTIVES: Although opioids have not demonstrated efﬁ cacy in treating ﬁ bromy-
algia (FM) and pose a risk for addiction, they are commonly used to treat FM patients. 
This study assesses the mean annual per patient cost of FM-related opioid use in 
commercially insured FM patients. METHODS: Using the Thomson/Medstat Mar-
ketScan Commercial Claims Database, we identiﬁ ed all patients aged 18 years with 
continuous health plan eligibility in 2006 and q1 inpatient or q2 outpatient paid 
medical claims in calendar year 2006 with ICD-9-CM diagnosis code 729.1 (“FM
patients”). Rx medications designated as possibly related to FM treatment (“FM-
